Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and Neck

Summary

In this trial, the investigators would like to investigate the activity of LEE011 associated with cetuximab (standard of care for the SCCHN patients at this stade of the disease).

Timeline

Start

2015-04

Primary completion

2017-09-01

Completion

2018-09-01

Outcome

Outcome not reported

Stopped (Enrollment): “Decided by the investigator due to the difficulties to recruit”

Publications

• Seront E, Schmitz S, Papier M, van Maanen A, Henry S, Lonchay C, Rottey S, van Caloen G, Machiels JP. Phase 1 Study Evaluating the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib and Cetuximab in Recurrent/Metastatic p16-Negative Squamous Cell Carcinoma of the Head and Neck. Front Oncol. 2019 Mar 19;9:155. doi: 10.3389/fonc.2019.00155. eCollection 2019.

Drugs

Indications